Optimal Research

Optimal Research is a clinical research site network and contract research organization (CRO) specializing in the management and execution of Phase I-IV clinical trials. The company operates a network of dedicated research sites and integrated physician practices, providing pharmaceutical and biotechnology sponsors with streamlined access to patient populations and high-quality clinical data. Their core therapeutic expertise includes oncology, vaccines, infectious diseases, and women's health. Optimal Research offers comprehensive services such as site selection, regulatory support, and patient recruitment strategies designed to accelerate the drug development process. In 2014, the company was acquired by Clinipace Worldwide, which subsequently merged with dMed in 2021 to form the global CRO Caidya.